<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; monopoly</title>
	<atom:link href="http://www.tapanray.in/tag/monopoly/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why India Encourages Healthcare Innovation &#8211; but Refuses to Copy the Western IP Model</title>
		<link>http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model</link>
		<comments>http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/#comments</comments>
		<pubDate>Sun, 21 Dec 2025 10:43:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[exclusion]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[incision]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[logic]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[monopoly]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[orthodoxy]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[western]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11013</guid>
		<description><![CDATA[Debates on pharmaceutical innovation often polarize quickly into pro-IP and anti-IP camps. This article deliberately avoids that binary. It examines why India encourages innovation while resisting blind replication of Western IP frameworks—and why that distinction matters for healthcare outcomes. Innovation &#8230; <a href="http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Abbott – Piramal deal: the way future is expected to shape up</title>
		<link>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=abbott-piramal-deal-the-way-future-is-expected-to-shape-up</link>
		<comments>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/#comments</comments>
		<pubDate>Mon, 31 May 2010 01:30:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[expected]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[monopoly]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[valuation]]></category>
		<category><![CDATA[way]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=421</guid>
		<description><![CDATA[In my view, these are still very early days for such acquisitions of large domestic Indian pharmaceutical companies by the Global Pharma majors to gain momentum in the country. However, there is no doubt that in the near future, we &#8230; <a href="http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
